Peregrine Pharmaceuticals (NASDAQ: PPHM) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Peregrine Pharmaceuticals to related businesses based on the strength of its risk, institutional ownership, dividends, profitability, earnings, analyst recommendations and valuation.


This table compares Peregrine Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Peregrine Pharmaceuticals -23.15% -38.19% -16.66%
Peregrine Pharmaceuticals Competitors -13,404.97% 246.04% -20.09%

Earnings & Valuation

This table compares Peregrine Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Peregrine Pharmaceuticals $79.10 million -$17.42 million -5.24
Peregrine Pharmaceuticals Competitors $579.30 million $241.72 million -6.57

Peregrine Pharmaceuticals’ rivals have higher revenue and earnings than Peregrine Pharmaceuticals. Peregrine Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Peregrine Pharmaceuticals has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals’ rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Peregrine Pharmaceuticals and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peregrine Pharmaceuticals 0 0 1 0 3.00
Peregrine Pharmaceuticals Competitors 114 749 1612 58 2.64

Peregrine Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 198.51%. As a group, “Biopharmaceuticals” companies have a potential upside of 5.27%. Given Peregrine Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Peregrine Pharmaceuticals is more favorable than its rivals.

Insider & Institutional Ownership

45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 4.9% of Peregrine Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.